Thank you for Subscribing to Life Science Review Weekly Brief
×
Life Science Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review
Top 10 CROs - 2021
New categories of emerging biologics and advances in cell and gene therapies are driving an evolutionary change in the contract research organization industry as these companies adapt their organizations to supply the services needed today. The rapid growth and uptake of technologies, such as CRISPR, CAR T cells, bispecifics and more, are significantly influencing the landscape of biotech and pharma drug development. To keep pace and provide the required support, CROs are investing in cutting-edge science and growing their service offerings to facilitate the field.
The last few years have seen tremendous consolidation in both the pharmaceutical and contract research industries. The impact among pharma companies has created a heightened demand for productivity. Consequently, CROs have struggled to find their footing in a business where the number of customers has shrunk and the demand for speed and cost-effectiveness has risen. Delivering service excellence when customers' names and addresses are changing regularly is a challenge, resulting in disrupted continuity, broken lines of communication, and policies and relationships thrown into disarray.
Among the many ways CROs can help increase productivity, the greatest potential lies in the application of their scientific expertise. Pharma companies possess indisputable expertise in a variety of areas, but they cannot span the entire spectrum of drug discovery and development. A CRO's scientific acumen can offer a unique perspective as a consultant focused on providing specific solutions. This is most important at the earliest levels of research.
CROs are unique in that they have seen and solved an enormous variety of challenges. What distinguishes a preferred partner from an average CRO is how well they've learned from their experience. A knowledge-based CRO can apply valuable intellectual resources to a wide scope of issues, making it a powerful ally.
The drug discovery and development industry faces formidable challenges, but the opportunities are there for those with the tools to exploit them. How significant a role CROs will play depends on their ability to prove their long-term worth by providing not just services but solutions.
We present to you, “Top 10 CROs 2021.”
Nominate a Company
Our subscribers nominate the companies with whom they have collaborated and gotten results. If you think there is a company that deserves to be on our upcoming prestigious annual list of Top 10 CROs , please write to us about them and the reasons you think they need to be on the list
-
Frontage provides integrated, science-driven product development services, ranging all the way from drug candidate evaluation to drug development. Today, the company is enabling many innovator, generic, and consumer health companies of all sizes to file IND, NDA, ANDA, BLA and 505(b)(2) submissions in global markets allowing for successful development of important therapies and products for patients. Frontage is committed to providing rigorous scientific expertise to ensure the highest quality and compliance. With the company’s assistance, the clients are able to advance hundreds of molecules through development to commercial launch in global markets
We help innovator, generic, and consumer health companies to file IND, NDA, ANDA, BLA, and 505(b) (2) submissions in global markets, ensuring successful development of important therapies and products for the patients
—Song Li, CEO
Frontage
501 - 1,000
Management
Song Li, CEO
CROs by Frontage :
- Clinical
- DMPK
- preclinical studies
- Formulation development
- API
- GMP clinical trial materials manufacturing
- CRO
- and gene therapy
-
ICON plc offers a full range of consulting, development and commercialisation services that enable pharmaceutical, biotechnology, medical device, and government and public health organisations to accelerate the development of drugs and devices. The company develops integrated technologies to significantly enhance the efficiency and productivity of its clients’ drug and device development programs, providing true transparency across all areas of a stud
Dr. Steve Cutler, CEOWe went very close to making a significant acquisition about four years ago when I first came into the job. And over that period of time, we’ve been, looking at the market, looking at our competitors
Icon Plc
10,001 - 20,000
Management
Dr. Steve Cutler, CEO
CROs by Icon Plc :
- Medical Device
- Therapeutics
- Clinical Research Services
- Clinical Trials
- Patient Recruitment
-
MabPlex provides global CRO/CMO services in the development and manufacturing of biopharmaceuticals. The company offers contract services from DNA to finished biopharmaceutical goods. As a one-stop-shop for its partners, MabPlex provides services, all the way from early-stage development to commercialization, covering the entire spectrum—from gene sequencing, cell line development, process characterization, conjugation optimization to Current Good Manufacturing Practice (cGMP) for clinical and commercial manufacturing of final drug product
“Relying on extensive experience and advanced equipment, we provide high-quality service in accordance with the specific needs of our clients
—Jianmin Fang, Founding Chairman, Wei Chen, CEO, Xinfang Li, President, Scott Cooper, San Diego Site Head, Jennifer Kuo, Sr. Dir BD
MabPlex International
Management
Jianmin Fang, Founding Chairman, Wei Chen, CEO, Xinfang Li, President, Scott Cooper, San Diego Site Head, Jennifer Kuo, Sr. Dir BD
-
Founded in 2003, Machaon Diagnostics specializes in the diagnosis and monitoring of coagulation, platelet, rare disease, and genetics. Operating as a clinical reference laboratory, the company has grown into a team of clinicians, scientists, consultants, and technologists that bring more than 400 years of combined expertise to the field of laboratory medicine. Machaon Diagnostics employs a NexGen sequencing technique allowing for the rapid detection (<48 hours) of over 150 known or suspected mutations, deletions, and polymorphisms previously reported as associated with aHUS, which is a life-threatening, progressive, and genetic disease
Machaon Diagnostics
Less than 100
Management
Michael Ero, Founder and CEO
CROs by Machaon Diagnostics :
- Coagulation
- Platelet Function
- Immunology
- Chemistry
- Gene Sequencing
- Molecular Diagnostics
- Clinical Trial Services
- Assay Design
- Research and Development
- Contract Research (CRO) Services
- and Rare Disease
-
-
Tergus Pharma is an end-to-end service provider for topical pharmaceuticals development. The company acts as an extension of their client’s team and provides support through the entire drug development lifecycle. With their services, pharma companies do not need to worry about the nuances of commercial drug development and manufacturing processes. Starting with high-quality R&D services at the pre-clinical stage, Tergus extends its capabilities to early skin biology services and clinical supplies manufacturing to deliver end-to-end development continuity
We are a CDMO with unmatched capabilities in dermatological drug development and manufacturing
—Dr. Vijendra Nalamothu, Chairman & CEO
Tergus Pharma
Less than 100
Management
Dr. Vijendra Nalamothu, Chairman & CEO
CROs by Tergus Pharma :
- Topical Product Development
- Analytical Testing Laboratory
- Contract Research Organization
- pharmaceutical manufacturing
- and topical pharmaceutical manufacturing
-
Crown Bioscience
Crown Bioscience, Inc. is a platform technology company providing drug discovery and development services in the areas of Oncology and Inflammation. CrownBio helps biopharmaceutical companies solve some of today's most pressing challenges in oncology with an offering of end-to-end preclinical solutions, a unique collection of ready-to-run, well-validated in vitro, in vivo, and ex vivo models, and cutting-edge technologies
Crown Bioscience
501 - 1,000
Management
Armin Spura, CEO
CROs by Crown Bioscience :
- Biomarker Discovery
- Validated Xenograft Models
- Cancer Cell Based Assays
- HuPrime PDX (Patient-Derived Xenograft) models
- Human Surrogate (Avatar) Drug Development
- Oncology Drug Development
- and Organoids
-
Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective
Medpace
1,001 - 5,000
Management
Jesse Geiger, President
CROs by Medpace :
- Clinical Research
- Medical Device and Diagnostics
- Clinical Monitoring
- Clinical Trial Management
- Bioanalytical Laboratories
- Imaging & ECG Core Labs
-
NAMSA
Helping medical device Sponsors improve healthcare since 1967, NAMSA is the only 100% medical device-focused, full continuum Contract Research Organization (CRO). Driven by our global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, we are the industry’s premier, trusted partner for successful development and commercialization outcomes
NAMSA
1,001 - 5,000
Management
John Gorski, President and CEO
CROs by NAMSA :
- Clinical Research
- Regulatory Consulting
- Research & Development Support
- Lot Release Testing
- Sterility Assurance Products
- and Reimbursement
-
Parexel
Parexel is focused on the development of innovative new therapies to improve the world’s health. They do this by providing a suite of groundbreaking biopharmaceutical development services that help customers across the globe transform scientific discoveries into new treatments for patients. From clinical trial design to regulatory and consulting services to commercial and market access, their therapeutic, technical, and functional ability is underpinned by a deep conviction in what they do
Parexel
10,001 - 20,000
Management
Jamie Macdonal, CEO
CROs by Parexel :
- Regulatory and product development consulting
- clinical research organization
- pharmacovigilance
- biotechnology
- biotech
- and market access
-
QPS Holdings
QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. They are passionate about their work, creating value for patients and customers while generating opportunities for employees to thrive
QPS Holdings
1,001 - 5,000
Management
Benjamin Chien, President and CEO
CROs by QPS Holdings :
- DMPK
- Translational Medicine
- Toxicology
- Bioanalysis
- Clinical Pharmacology
- Clinical Research
- Contract Research
- CRO
